

Risks and Tricks of Alloimmunization in Sickle Cell Disease

Karina Yazdanbakhsh, PhD
Executive Director, Research Institute
Head, Laboratory of Complement Biology
New York Blood Center

NVB, May 15th, 2019

Objectives

- Describe the effects of hemolysis on T cells from patients with sickle cell disease on transfusion therapy
- Discuss innate immune response to hemolysis in transfused patients with sickle cell disease
- Describe the effects of transfusions on circulating patrolling monocytes: protection against vaso-occlusion in sickle cell disease

SCD-Transfusion therapy

- An estimated 60-80% will receive at least one transfusion by the age of 20
- Blood transfusion is recommended therapy for SCD complications: stroke, acute chest syndrome, multi-organ failure syndrome and severe anemia and...



Transfusion Complications in SCD


- Alloimmunization
 - Life-threatening transfusion reactions
 - Difficulty obtaining compatible units, resulting in potentially critical delays in blood transfusion
- Higher alloimmunization rates
- Major reason: Differences in red blood cell antigen expression frequencies between the mostly Caucasian donor base and the mostly African-American SCD patients

Antigen-matching for Transfusions in SCD

- Majority of patients do not make antibodies therefore prophylactic matching is costly
- Supply logistics: RBCs of unusual phenotype are a limited resource and should potentially be reserved for patients who require these antigenic specifications
- Identify **immune responsiveness of the patient**, to predict in advance which patients will make antibodies

Hemolysis in SCD

- Intravascular hemolysis in SCD
- Heme scavenging/removal system (hemopexin and haptoglobin) is overwhelmed
- Anti-inflammatory heme oxygenase 1 (HO-1) breaks down heme; upregulated in SCD




Hypothesis: *Ability of the immune cells to handle ongoing hemolysis is critical in alloimmunization*


T cells critical for B cell help/Ab production

*Does heme/hemin alter T cell
proliferation/polarization?*


Anti-CD3 stimulation assay



PBMC
+CFSE






Anti-CD3
7 days



Tregs


Th17

Th1




Heme response in Healthy Donors

Proliferation



Hemin


Treg




Hemin

Heme response in Healthy Donors


Proliferation




Treg




Th1



Alloimmunized Patients with SCD have Blunted Treg/Th1 Expansion in Response to Heme




Analysis of T cell Priming by Dendritic Cells (DCs)





TLR ligands for DC maturation:

- LPS (TLR-4)
- LPS+IFN- γ (TLR-4/Stat-1)
- R848 (TLR7/8)




Impaired Inhibition of Th1 Priming in Response to Heme in Alloimmunized SCD Patients

- Healthy Donor Controls
- Non-alloimmunized SCD Patients
- Alloimmunized SCD Patients




Hypothetical model




Mechanism of Altered Innate Immune Reactivity by Free Heme


Detection of DC Maturation



Impaired Downregulation of CD83 Maturation Marker on DCs in Alloimmunized Patients in Response to Heme




Pro-oxidant and Pro-inflammatory Effects of Cell Free Heme in Endothelial Cells





John D. Belcher et al.
Blood 2014;123:377-390


Regulation of CD83 Expression by Free Heme is through TLR-4



■ Healthy Donor Controls
 ■ Non-alloimmunized SCD Patients
 ■ Alloimmunized SCD Patients




Heme-driven NF- κ B Expression in DCs




Godefroy et al, Hematologica 2016


Non Alloimmunized DC activation



Alloimmunized DC activation




Patrolling Monocytes



- Phagocytose cellular debris derived from damaged endothelial cells
- Control endothelial damage in atherosclerosis models and clear vascular amyloid beta in Alzheimer's disease
- SCD express high levels of HO-1 in patrolling monocytes: control T cell anti-inflammatory profile in SCD under hemolytic conditions

(Zhong... Yazdanbakhsh, (2014) *Jl* 193(1):102-10)



Hypothesis: HO-1 expressing patrolling monocytes clear heme damaged endothelial cells and sickle RBC attached to ECs in SCD, dampening inflammation


Carlin et al. (2013) *Cell* 153(2): 362-375.

Quintar et al. (2017) *Circ Res* 120(11):1789-1799.

Michaud et al. (2013) *Cell Rep* 5(3):646-653.






Zhong ...Yazdanbakhsh. (2014). *J Immunol* 193(1):102-110.

Protection from plasma cell-free hemoglobin and heme in sickle cell disease






Victor R. Gordeuk Blood 2018;131:1503-1505  blood

HO-1 expressing Patrolling Monocyte Characterization in SCD





Expanded subpopulation of circulating patrolling monocytes expressing high levels of HO-1 in SCD

Phagocytosed RBCs in Circulating SCD PMOs







RBC engulfed material is present in the circulating PMOs of patients with SCD which is further increased during crisis, and may lead to reduced PMo numbers.






In vivo, PMo uptake sickie RBCs, but not control RBCs in part through monocyte CD11a

Cryoprotective HO-1 Expression in Sickle RBC Phagocytosed PMo



Sickle RBC engulfed PMo up-regulate HO-1 which in turn is cytoprotective



Manipulation of PMo Numbers Affects Sickle RBC Stasis In Vivo



Depletion of PMo numbers increases sickle RBC attachment to vascular endothelium and RBC stasis in SCD mice, while increasing their nos protects against tissue/organ damage



Can transfusions help PMo survival?

Increased Survival of PMos in In Vitro transfusion model



“In vitro transfusions” with healthy donor RBCs reduce PMo uptake of sickle RBCs, leading to improved survival of PMOs.

Increased Survival of PMOs In Vivo After Transfusion



Transfusions with healthy donor RBCs reduce PMo uptake of sickle RBCs, leading to improved survival of PMOs.

Liu et al. *Blood* 2019



- Yunfeng Liu
- Hui Zhong
- Emmanuelle Godefroy
- Weili Bao
- Woelsung Yi
- Vijendra Ramlall

- Patricia Shi
- Xiuli An
- Avital Mendelson
- Francesca Vinchi
- Cheryl Lobo

Montefiore Hospital

- Deepa Manwani
- Caterina Minniti
- Joan Uehlinger

Children's Hospital of Philadelphia

- David Friedman
- Stella Chou

University of Illinois, Chicago

- Sally Campbell-Lee
- Victor Gordeuk



Funding Support

NIH/NHLBI:

R01HL121415

R01HL130139

American Heart Association

